Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dendreon sells Victrelis royalties to CPPIB for $125mm

Executive Summary

Cancer therapeutics company Dendreon Corp. has decided to sell its royalty interest related to the recently approved hepatitis C drug Victrelis (boceprevir) to CPPIB Credit Investments for $125mm in cash. The therapy was originally developed by Corvas International and Schering-Plough under a 1997 agreement that held S-P (now owned by Merck & Co. Inc.) responsible for undisclosed royalties to Corvas. When Dendreon merged with Corvas in 2003, it inherited the royalty payments, and has now chosen to boost its cash position through the sale to CPPIB. The purchase marks the second in as many months for the investor (which is owned by the CPP Investment Board); in November, it paid $75mm for the US royalties to Pozen's migraine treatment Treximet.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Royalty Sale

Related Companies